-- Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.
The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.
The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.
Shares of Arcus Biosciences were down 5% in Monday trading.
Price: $23.05, Change: $-1.20, Percent Change: -4.95%